Logo image of VIRI

VIRIOS THERAPEUTICS INC (VIRI) Stock Fundamental Analysis

USA - NASDAQ:VIRI - US92829J1043 - Common Stock

0.155 USD
+0.02 (+12.4%)
Last: 10/8/2024, 8:00:02 PM
0.1452 USD
-0.01 (-6.32%)
After Hours: 10/8/2024, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VIRI. VIRI was compared to 534 industry peers in the Biotechnology industry. While VIRI seems to be doing ok healthwise, there are quite some concerns on its profitability. VIRI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VIRI has reported negative net income.
VIRI had a negative operating cash flow in the past year.
In the past 5 years VIRI always reported negative net income.
In the past 5 years VIRI always reported negative operating cash flow.
VIRI Yearly Net Income VS EBIT VS OCF VS FCFVIRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

VIRI has a Return On Assets of -145.66%. This is amonst the worse of the industry: VIRI underperforms 85.31% of its industry peers.
With a Return On Equity value of -168.89%, VIRI is not doing good in the industry: 66.02% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -145.66%
ROE -168.89%
ROIC N/A
ROA(3y)-124.88%
ROA(5y)-235.88%
ROE(3y)-138.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VIRI Yearly ROA, ROE, ROICVIRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

VIRI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VIRI Yearly Profit, Operating, Gross MarginsVIRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

VIRI has more shares outstanding than it did 1 year ago.
VIRI has more shares outstanding than it did 5 years ago.
VIRI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VIRI Yearly Shares OutstandingVIRI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 5M 10M 15M
VIRI Yearly Total Debt VS Total AssetsVIRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -28.27, we must say that VIRI is in the distress zone and has some risk of bankruptcy.
VIRI's Altman-Z score of -28.27 is on the low side compared to the rest of the industry. VIRI is outperformed by 89.56% of its industry peers.
There is no outstanding debt for VIRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.27
ROIC/WACCN/A
WACCN/A
VIRI Yearly LT Debt VS Equity VS FCFVIRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

VIRI has a Current Ratio of 7.27. This indicates that VIRI is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.27, VIRI is doing good in the industry, outperforming 68.85% of the companies in the same industry.
VIRI has a Quick Ratio of 7.27. This indicates that VIRI is financially healthy and has no problem in meeting its short term obligations.
VIRI has a Quick ratio of 7.27. This is in the better half of the industry: VIRI outperforms 69.03% of its industry peers.
Industry RankSector Rank
Current Ratio 7.27
Quick Ratio 7.27
VIRI Yearly Current Assets VS Current LiabilitesVIRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.36% over the past year.
EPS 1Y (TTM)56.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

VIRI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.70% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.86%
EPS Next 2Y18.28%
EPS Next 3Y6.76%
EPS Next 5Y12.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIRI Yearly Revenue VS EstimatesVIRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 20M 40M 60M
VIRI Yearly EPS VS EstimatesVIRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIRI. In the last year negative earnings were reported.
Also next year VIRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIRI Price Earnings VS Forward Price EarningsVIRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIRI Per share dataVIRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.28%
EPS Next 3Y6.76%

More info and screens

0

5. Dividend

5.1 Amount

VIRI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIOS THERAPEUTICS INC

NASDAQ:VIRI (10/8/2024, 8:00:02 PM)

After market: 0.1452 -0.01 (-6.32%)

0.155

+0.02 (+12.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2024-08-08/bmo
Earnings (Next)11-11 2024-11-11/bmo
Inst Owners99.68%
Inst Owner Change0%
Ins Owners83.34%
Ins Owner Change0%
Market Cap172.05K
Revenue(TTM)N/A
Net Income(TTM)-5296010
Analysts80
Price Target1.43 (822.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.49%
Min EPS beat(2)-71.57%
Max EPS beat(2)22.6%
EPS beat(4)3
Avg EPS beat(4)5.94%
Min EPS beat(4)-71.57%
Max EPS beat(4)38.08%
EPS beat(8)6
Avg EPS beat(8)18.36%
EPS beat(12)10
Avg EPS beat(12)18.83%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.33%
EPS NY rev (1m)0%
EPS NY rev (3m)18.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.05
P/tB 0.05
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-3.77
FCFYN/A
OCF(TTM)-3.77
OCFYN/A
SpS0
BVpS2.83
TBVpS2.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -145.66%
ROE -168.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-124.88%
ROA(5y)-235.88%
ROE(3y)-138.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.27
Quick Ratio 7.27
Altman-Z -28.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y19.86%
EPS Next 2Y18.28%
EPS Next 3Y6.76%
EPS Next 5Y12.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.44%
OCF growth 3YN/A
OCF growth 5YN/A

VIRIOS THERAPEUTICS INC / VIRI FAQ

What is the fundamental rating for VIRI stock?

ChartMill assigns a fundamental rating of 2 / 10 to VIRI.


Can you provide the valuation status for VIRIOS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to VIRIOS THERAPEUTICS INC (VIRI). This can be considered as Overvalued.


What is the profitability of VIRI stock?

VIRIOS THERAPEUTICS INC (VIRI) has a profitability rating of 0 / 10.